cyrilzakka/clinical-trials huggingface dataset:
Electrocardiographic Changes Among Epileptic and Non Epileptic Seizures in Children at Sohag University Hospital

Epilepsy is a chronic disease triggered by increased impulsiveness of nerve cells in the brain and may require a lifelong treatment. Epilepsy is confirmed by two or more unprovoked seizures in more than 24 hours. Febrile Convulsion is another type of seizure occurring due to fever over 38 °C without a history of convulsion, CNS infection, electrolyte imbalance, metabolic disorder, intoxication, and trauma. Unlike epileptic seizures, there are non-epileptic seizures such as Breath Holding Spells that affect children's behaviors and often look like epileptic seizures.

QT parameters elongation show the danger of dysrhythmia and unexpected sicknesses such as cardiomyopathy, mitral valve prolapse, ischemic coronary illness, and kidney disorders.

Many investigators have reported changes in QT parameters in various diseases such as diabetes mellitus, celiac disease, thalassemia , epilepsy ,Breath holding spells and febrile seizure.


Eligibility Criteria:
Inclusion Criteria:

* children with drug resistant epilepsy.
* febrile seizures.
* age of 1 year to 12 years.

Exclusion Criteria:

* age below 1 year and above 12 years
* children with convulsion secondary cns infection , encephalitis, encephalopathy , toxic and metabolic problem
Biomarkers of Prednisolone Treatment (P05888)

Primary objective:

* To identify a biomarker or biomarker-set for the adverse metabolic effects of various doses of prednisolone treatment.

Secondary objectives:

* To describe the PK of prednisolone and PD of a series of biomarkers.
* To identify biomarkers that reflect side effects of prednisolone.
* To elucidate part of the mechanisms by which prednisolone induces metabolic changes.


Eligibility Criteria:
Inclusion Criteria:

* 22 \< BMI \< 30
* fasting glucose \< 5.6 mmol/L and glucose \< 7.8 mmol/L 2hr after OGTT
* able and willing to sign informed consent
* history of good physical and mental health
* subject smokes less than 5 cigarettes per day
* able to keep a normal day and night rhythm

Exclusion Criteria:

* allergy to prednisolone
* glucocorticoid use during last 3 months prior to study
* use of any drug or substance
* history of familiar diabetes type 2
* clinically relevant history or presence of any medical disorder
* clinically relevant abnormal lab or ECG
* positive drug or alcohol screen, positive hepatitis B or C surface antigen
* donation of blood (\>100 mL) within 90 days prior to the first dose
Acupuncture for Overactive Bladder in Adults

The purpose of this study is to assess the effectiveness and safety of acupuncture for treating overactive bladder in adults.

This randomized, controlled trial is aimed to assess the effectiveness and safety of acupuncture in the treatment of overactive bladder (OAB) in adults. Eligible participants will be randomly allocated to acupuncture or sham acupuncture.

To minimize the evaluation bias, the outcome assessors and statisticians will be masked to treatment allocation besides participants.

Eligibility Criteria:
Inclusion Criteria:

* Present symptoms of urinary frequency and urgency for more than 3 months.
* With a total score of more than 3 points on the overactive Bladder Symptom Score (OABSS) and a score of more than 2 points on question 3 of OABSS.

Exclusion Criteria:

* With other lower urinary tract disorders (e.g. urinary tract infection, bladder outlet obstruction, neurogenic bladder, interstitial cystitis, etc.)
* With previous pelvic floor surgery or a post-void residual urine volume more than 100 mL.
* With neurological disease or psychiatric illness.
* Taking medications affecting lower urinary tract function.
* With contraindications to acupuncture.
* Pregnant women.
Vasodilatory and Metabolic Effects of Glucagon-like Peptide-1 in Periphery Circulation in Patients With and Without Type 2 Diabetes Mellitus

Diabetes and high blood pressure are risk factors for developing heart disease. An increase in the number of diabetes patients is expected. This increases the number of patients with heart disease, and since the vast majority with diabetes die from heart disease, it is extremely important to investigate how these diseases can be prevented and treated.

Studies in animals have shown that intestinal hormone glucagon-like peptide-1 (GLP-1) can expand blood vessels, thus lowering blood pressure, but it is not known whether the effects is found in humans, which we will investigate.

Studies have also shown that GLP-1 lowers blood sugar, but it is unclear whether this is solely due to increased insulin production, weight loss associated with GLP-1 intake or GLP-1 has an effect on the muscles which increases the uptake of sugar. We investigate whether GLP-1 enhances the absorption of sugar in the leg.

The investigators also examines whether these effects are greater in people with diabetes then in healthy.


Eligibility Criteria:
Inclusion Criteria:

* Written informed consent
* T2DM according to WHO's criteria (only T2DM subjects)

Exclusion Criteria:

* Anemia
* T1DM
* Severe liver or renal disease
* Severe heart disease
* Atrial fibrillation
The Effect Vitamin D on the Recovery Rate of Bell Palsy

Patients aged between 18-65 who visit the Physical Medicine and Rehabilitation outpatient clinic diagnosed with Bell Palsy will be included in the study. The patients' Bell Palsy grade will be evaluated by Houseman Brahman (HB) Scale and their disability level will be evaluated by Facial Disability Index (FDI). Their serum vitamin D level will be noted. The patients having vitamin D deficiency will be randomized into two groups. Group 1 will be given 50.000 IU/week vitamin D replacement for 8 weeks. All the patients will be included in a standard physical therapy and home exercise program. Both groups will be asked for a control visit at weeks 8.Their clinical recovery will be evaluated by HB staging and FDI by the Physical Medicine and Rehabilitation specialist who is blind to the randomization.

Patients aged between 18-65 who visit the Physical Medicine and Rehabilitation outpatient clinic diagnosed with Bell Palsy will be included in the study. Facial palsy stages of patients will be graded from 1 to 6 according to the Houseman Brahman (HB) staging system. In order to determine the disability criteria of the patients, a form called Facial Disability Index (FDI)-Facial Disability Index will be filled. This scale consists of 10 questions and is a validated test evaluating the physical and social function of the patient. The patients having vitamin D deficiency will be randomized into two groups. One group will be getting a vitamin d replacement treatment for 8 weeks. A physical therapy program in the form of a standard exercise program including electrical stimulation and facial paralysis exercises will be organized for all the patients. The patients will be evaluated at 8th week by HB and FDI.

Eligibility Criteria:
Inclusion Criteria:

* Being cooperative-orientated
* Willing to participate in the Physical Therapy home exercise program

Exclusion Criteria:

* Being Non cooperative, disorientated
* Failure to comply with the Physical Therapy home exercise program
* History of malignancy
* Additional neurological disease
* Having cranial pathologies
SONOthrombolysis in Patients With an ST-segment Elevation Myocardial Infarction With fibrinoLYSIS (SONOSTEMI-LYSIS) Trial

This study will assess the safety and feasibility of sonothrombolysis in the acute management of STEMI undergoing reperfusion therapy with systemic fibrinolysis as part of a pharmacoinvasive approach

This study is an open label, single-centre, randomized investigation of sonothrombolysis in 60 adult patients presenting with STEMI within 6 hours of the onset of clinical symptoms and receiving perfusion therapy with fibrinolysis as part of a pharmacoinvasive strategy.

Patients will be randomized 2:1 to either adjunct treatment with sonothrombolysis or standard therapy alone according to the current American College of Cardiology/American Heart Association (ACC/AHA) or European Society of Cardiology (ESC) STEMI and PCI guidelines. All patients will receive serial echocardiography assessments during and after reperfusion with the final ECHO assessment at 90 days (+/- 7d) post reperfusion. Patient outcomes (medical records review) will be followed for 1 year after reperfusion.

Eligibility Criteria:
Inclusion Criteria:

* Patients presenting with STEMI within 6 hours of symptom onset and:

  1. Are expected to receive reperfusion therapy with fibrinolysis
  2. Have a high-risk STEMI ECG as defined as:

     * \>2mm ST-segment elevation in 2 anterior or lateral leads; or
     * \>2mm ST-segment elevation in 2 inferior leads coupled with ST-segment depression in 2 contiguous anterior leads for a total ST-segment deviation of \>4mm
  3. Age \>30 years
  4. Adequate apical and/or parasternal images by echocardiography

Exclusion Criteria:

* 1. Isolated inferior STEMI without anterior ST-segment depression 2. Previous coronary bypass surgery 3. Cardiogenic shock 4. Known or suspected hypersensitivity to ultrasound contrast agent used for the study 5. Life expectancy of less than two months or terminally ill 6. Known bleeding diathesis or contraindication to glycoprotein 2b/3a inhibitors, anticoagulants, or aspirin 7. Known large right to left intracardiac shunts 8. Patient received another investigational medication or treatment within 30 days prior to presentation with STEMI
Study To Compare Single Dose Of Three Modified Release Formulations Of PF-04937319 With Immediate Release Material-Sparing-Tablet (IR MST) Formulation Previously Studied In Adults With Type 2 Diabetes Mellitus.

Study B1621015 will characterize bioavailability, tolerability and pharmacodynamics of three modified release formulations of PF-04937319 compared with the immediate release material-sparing-tablet (IR MST) formulation in adults with type 2 diabetes.


Eligibility Criteria:
Inclusion Criteria:

* Adults with type 2 diabetes, on stable background metformin therapy either alone or in combination with another oral anti-diabetic agent (OAD) excluding thiazolidinediones (TZDs)

Exclusion Criteria:

* Patients with cardiovascular event within 6 months of screening
* Patients with diabetic complications
* Female subjects who are pregnant or planning to become pregnant
* Subjects with unstable medical conditions (eg, hypertension)
Gaming and Training Combined to Help Adolescents Get More Physically Active

The purpose of this study is to investigate if playing a newly developed videogame that requires physical activity (e.g. exergame), leads to increased physical activity and health benefits in children and adolescents who do not regularly participate in endurance training. Health benefits will be expressed in physical fitness (maximal oxygen consumption), blood markers of a healthy heart, body composition and objectively measured physical activity. Gaming frequency of the participants will be registered throughout the 24 week intervention period.


Eligibility Criteria:
Inclusion Criteria:

* Not regularly participating in endurance training
* Sedentary (\<60 mins daily moderate/vigorous intensity physical activity)
* Play video games \> 10 hours/week (self-reported)
* Able to ride a bike for up to 60 minutes

Exclusion Criteria:

* Known cardiovascular disease
* Type I diabetes
Vaginal Laser Therapy in Breast Cancer Survivors

This study evaluates the efficacy of vaginal CO2 laser therapy in breast cancer survivors with symptoms of Genitourinary Syndrome of Menopause. Half of participants will receive active laser therapy, while the other half placebo therapy.


Eligibility Criteria:
Inclusion Criteria:

* breast cancer history
* dyspareunia
* dryness

Exclusion Criteria:

* Active genital infection (i.e herpes, vaginitis)
* Prolapse stage \>=2
* Underlying pathologies that could interfere with the protocol compliance
Juvenile Rheumatoid Arthritis Research Registry

Juvenile rheumatoid arthritis (JRA) is the most common chronic inflammatory disease in children, and may be related to genetics. Having two siblings who both have JRA in one family is rare. The purpose of this registry is to collect patient information and blood samples from qualifying JRA siblings and their families. The goal of the registry is to further understanding of JRA as related to genetics.

JRA is the most common chronic inflammatory pediatric rheumatic disease. JRA may be related to a complex genetic trait. It is rare to have two or more affected siblings, or sibpairs, within one family. The JRA ASP (Affected Sibpair) Registry is a nationwide effort and will collect information and blood samples from JRA sibpairs and their families. Unaffected family members (e.g., mother, father, and unaffected children) are also invited to participate.

Patients and their families may enroll in the registry in one of two ways: patients may contact the registry directly, or they may be referred to the registry through their physician. Once the family has qualified to join the registry, the family will be asked to complete a questionnaire on the medical history of their JRA-affected members. Physicians of the JRA-affected members will be asked to complete questionnaires about their patients' conditions. Family members will also be invited to provide a one-time blood sample. Information collected through the registry will help researchers identify genes involved in JRA susceptibility.

Eligibility Criteria:
Inclusion Criteria for Patients and Their Families:

* At least two members of a family diagnosed with juvenile rheumatoid arthritis (JRA)
* Informed consent from the family indicating willingness to participate in the registry
Bexarotene Treatment in Schizophrenia

In this proposed study, we aim to investigate the effects of Bexarotene (Targretin; LGD1069; 4-\[1-{5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl} ethenyl\] benzoic acid) on severity of psychopathology, cognitive impairment, and quality of life in schizophrenia patients in an open label trial. The rationale behind add-on oral bexarotene to ongoing antipsychotic treatment in schizophrenia patients is based on both the retinoid dysregulation hypothesis (Goodman, 1995) and the growth factors deficiency and synaptic destabilization hypothesis (Moises et al, 2002) of schizophrenia. In this clinical trial, a novel regimen of low dose bexarotene (Targretin, 75 mg/day) will be added for 6 weeks to the standard treatment of 15 schizophrenia patients on stable antipsychotic treatment. Participants will be assessed at baseline and after 2, 4 and 6 weeks of treatment. A battery of research instruments will be used for assessment of efficacy and safety (psychopathology, and side effects). In addition, cholesterol and triglyceride levels, liver and thyroid function tests and a blood cell count will be monitored at baseline and during therapy.


Eligibility Criteria:
Inclusion Criteria:

* age 18-60
* schizophrenia
* stable blood parameters
* normal baseline fasting triglyceride
* ability to sign informed consent

Exclusion Criteria:

* lipid abnormalities
* leukopenia or neutropenia
* organic brain damage (mental retardation)
* alcohol or drug abuse
* renal disease
* hepatic dysfunction
* history of pancreatitis
* thyroid axis alterations
* suicide attempt in past year
* cataracts
* systemic treatment with more than 15,000IU vitamin A daily
* patients with known hypersensitivity to bexarotene or other components of the product
* pregnant women
Chronic Heart Failure Analysis and Registry in the Tohoku District 2 (CHART-2 Study)

Chronic Heart Failure Analysis and Registry in the Tohoku District 2 (CHART-2 Study) is a large, prospective, hospital-based cohort study to investigate the following:

* Characteristics of patients with chronic heart failure and prognostic risks of these patients.
* Characteristics of patients with high risk for heart failure and critical factors which predict the development of symptomatic heart failure in these patients.
* The incidence and prognostic impact of metabolic syndrome in patients with chronic heart failure.
* The association between metabolic syndrome and the development of symptomatic heart failure.

The CHART-2 Study is a multicenter prospective observational cohort study identifying the characteristics, mortality and prognostic risks of patients with overt HF and patients without HF but who are at high risk for disease progression of cardiovascular diseases (CVD).

The purposes of the study are as follows:

1. to elucidate characteristics of patients with overt HF and the associated prognostic risks
2. to elucidate characteristics of patients at risk for HF and the factors associated with CVD progression
3. to elucidate factors associated with the development of AHFS
4. to elucidate prevalence and prognostic impact of metabolic syndrome (MetS) in patients with overt HF
5. to elucidate the association between MetS and the development of AHFS
6. to elucidate the prevalence and prognostic impact of malignancy in patients with CVD
7. to elucidate the prevalence of patients needing home nursing care and the characteristics of bedridden patients with CVD.

Eligibility Criteria:
Inclusion Criteria:

* Structural heart disease but without signs or symptoms of heart failure.
* Structural heart disease with prior or current symptoms of heart failure.
* Refractory heart failure requiring specialized interventions.
* Patients with prior cardiovascular surgery or percutaneous coronary intervention and those who need such interventions.

Exclusion Criteria:

* Patients with age\<20 years old.
* Patients who refused to participate.
Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration

Patients with PKAN will be treated with the iron chelator deferiprone for 18 months. Only patients who have completed the earlier study TIRCON2012V1 (NCT01741532), a double-blind placebo-controlled trial in which participants were randomized to receive either deferiprone or placebo for 18 months, are eligible to enroll.

TIRCON2012V1-EXT is a multi-center, single-arm, open-label study. All patients who completed the earlier study TIRCON2012V1 (NCT01741532) are eligible to take part. In the initial study, patients were randomized in a 2:1 ratio to receive 18 months of treatment with either the iron chelator deferiprone or placebo, respectively. In this extension study, all participants will receive deferiprone for 18 months. Thus, depending on which product was received earlier, patients will be on deferiprone for a total of either 1.5 years or 3 years. As in the earlier study, assessments will be carried out every six months to look at the safety of the drug and to see if patients are showing any improvement in dystonia and other symptoms of PKAN.

Eligibility Criteria:
Inclusion Criteria:

* Completed study TIRCON2012V1

Exclusion Criteria:

* Withdrew from the study TIRCON2012V1 for reasons of safety
* Plan to participate in another clinical trial at any time from the day of enrolment until 30 days post-treatment in the current study
Effects of Surgery Types in Patients With Pulmonary Nodules

The investigators aimed to compare the pre-post operative effects of video-assisted thoracoscopy surgery (VATS) and thoracotomy on pulmonary function, exercise capacity, physical activity level, respiratory and peripheral muscle strength, inspiratory muscle endurance, quality of life, fatigue, dyspnea perception and pain in patients with pulmonary nodules.

According to global cancer statistics, lung cancer accounts for 11.6% of all cancer cases and it is the most common type of cancer in the world. Surgery is the primary treatment approach, especially in early stages lung cancer. Cardiopulmonary fitness of patients with lung cancer is lower than healthy individuals due to the disease itself and treatments. Pulmonary function, exercise capacity and physical activity level are affected in lung cancer depending on the resected lung tissue and the type of surgery. VATS and thoracotomy surgeries, which are the most preferred techniques in lung cancer, have advantages and disadvantages over each other. There are few studies compared the early effects of two surgeries on the pulmonary function, exercise capacity, physical activity, quality of life and fatigue. And also, no study compared the effects of two surgeries on respiratory muscle endurance and peripheral muscle strength, previously.

According to sample size calculation, at least 15 patients with pulmonary lesion both VATS and thoracotomy groups would be included in the study. The demographic, physical and physiological characteristics were recorded from the patient files. Pulmonary function, functional exercise capacity, physical activity level, respiratory and peripheral muscle strength, inspiratory muscle endurance, quality of life, fatigue, dyspnea perception and pain were evaluated pre and two weeks after postoperative term. Primary outcomes were pulmonary function, functional exercise capacity and physical activity level. Secondary outcomes were respiratory and peripheral muscle strength, inspiratory muscle endurance, quality of life, fatigue, dyspnea perception and pain.

Eligibility Criteria:
Inclusion Criteria:

* Being between 18-80 years of age,
* Patients with pulmonary nodule who were planned lobectomy surgery with one of VATS or thoracotomy techniques,
* Being able to walk,

Exclusion Criteria:

* Any type of surgery planned except lobectomy,
* Having heart failure or atrial fibrillation,
* Having acute viral infections during all assessment,
* History of acute myocard infarction within last six months,
* Uncontrolled diabetes or hypertension,
* Having orthopedic, neurological and psychological disorders that influence the results of study.